What question did this study set out to answer?

The aim is to evaluate the efficacy of septal occluder devices for treating recurrent tricuspid regurgitation in high-risk patients.

March 31, 2026JACC Case ReportsOpen Access

Off-Label Use of Septal Occluder Devices for Recurrent Tricuspid Regurgitation Following TEER

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the efficacy of septal occluder devices for treating recurrent tricuspid regurgitation in high-risk patients.
Evaluated 4 high-risk patients with severe tricuspid regurgitation
Utilized off-label percutaneous closure with septal occluder devices
Employed right internal jugular access for better alignment and control
Conducted balloon test occlusion and ensured meticulous imaging
Stable anchoring and durable reduction in tricuspid regurgitation observed
Some devices embolized early, but others provided significant improvement
Outcomes varied from sustained symptom relief to persistent heart failure

No takes yet. Share an insight, caveat, or question.

Case reports demonstrate improvements in recurrent tricuspid regurgitation, suggesting a new treatment option.

Jaly et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark